DAB389IL-2 (Denileukin Diftitox, ONTAK): A New Fusion Protein Technology

Clinical Lymphoma

Volumn 1, Issue 1 SUPPL., 2000, Pages

  Foss, Francine M ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

DAB389IL 2; DAB486IL 2; Diphtheria toxin; Fusion toxins; Lymphoma; Pharmacokinetics

Indexed keywords

DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 2;

CHEMISTRY; CLINICAL TRIAL; HUMAN; REVIEW;

CLINICAL TRIALS; DIPHTHERIA TOXIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS;

EID: 0001776198     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.s.005     Document Type: Article

References (42)

1. O'Toole JE, Esseltine D, Lynch TJ, et al. Clinical trials with blocked ricin immunotoxins. Curr Top Microbiol Immunol 1998; 234:35-56.
2. Pai LH, Pastan I. Clinical trials With Pseudomonas exotoxin immunotoxins. Curr Top Microbiol Immunol 1998; 234:83-96.
3. Chaudhary V, Batra J, Gallo M, et al. A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins. Proc Natl Acad Sci USA 1992; 87:1066-1070.
4. Pelham H, Roberts L, Lord J. Toxin entry: how reversible is the secretory pathway? Trends Cell Biol 1992; 2:183-185.
5. Wales R, Roberts L, Lord J. Addition of an endoplasmic reticulum retrieval sequence to ricin A chain significantly increases its cytotoxicity to mammalian cells. J Biol Chem 1993; 268:23986-23990.
6. Endo Y, Mitsui K, Motizuki M, et al. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem 1987; 262:5908-5912.
7. Collier RJ. Structure-activity relationships in diphtheria toxin and Pseudomonas aeruginosa exotoxin A. Cancer Treat Res 1988; 37:25-35.
8. Brinkmann U, Pai LH, FitzGerald DJ, et al. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA 1991; 88:8616-8620.
9. Nichols J, Foss F, Kuzel TM, et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997; 33 (suppl 1):S34-S36.
10. Greenfield L, Johnson VG, Youle RJ. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987; 238:536-539.
11. Rolf JM, Eidels L. Structure-function analyses of diphtheria toxin by use of monoclonal antibodies. Infect Immun 1993; 61:994-1003.
12. Moya M, Dautry-Varsat A, Goud B, et al. Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin. J Cell Biol 1985; 101:548-559.
13. Morris RE, Gerstein AS, Bonventre PF, et al. Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation. Infect Immun 1985; 50:721-727.
14. Fuchs R, Schmid S, Mellman I. A possible role for Na+,K+-ATPase in regulating ATP-dependent endosome acidification. Proc Natl Acad Sci U S A 1989; 86:539-543.
15. Donovan JJ, Simon MI, Draper RK, et al. Diphtheria toxin forms trans-membrane channels in planar lipid bilayers. Proc Natl Acad Sci U S A 1981; 78:172-176.
16. Hoch DH, Romero-Mira M, Ehrlich BE, et al. Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes. Proc Natl Acad Sci U S A 1985; 82:1692-1696.
17. Lakkis F, Steele A, Pacheco-Silva A, et al. Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein. Eur J Immunol 1991; 21:2253-2258.
18. Wen ZL, Tao X, Lakkis F, et al. Diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion toxin. Internal in-frame deletion from Thr387 to His485 results in the formation of a highly potent fusion toxin which is resistant to proteolytic degradation. J Biol Chem 1991; 266:12289-12293.
19. Murphy JR, Bishai W, Borowski M, et al. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein. Proc Natl Acad Sci U S A 1986; 83:8258-8262.
20. Williams DP, Parker K, Bacha P, et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1987; 1:493-498.
21. Bacha P, Williams DP, Waters C, et al. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988; 167:612-622.
22. Walz G, Zanker B, Brand K, et al. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Proc Natl Acad Sci U S A 1989; 86:9485-9488.
23. Waters CA, Schimke PA, Snider CE, et al. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur J Immunol 1990; 20:785-791.
24. Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986; 232:727-732.
25. Waldmann TA. The multichain interleukin 2 receptor. A target for immunotherapy in lymphoma, autoimmune disorders, and organ allografts. JAMA 1990; 263:272-274.
26. Craig F, Banks P. Detection of the alpha and beta components of the interleukin-2 receptor using immunologic techniques. Mod Pathol 1992; 5:118a (Abstract).
27. Uchiyama T, Hori T, Tsudo M, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest 1985; 76:446-453.
28. Strauchen JA, Breakstone BA. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol 1987; 126:506-512.
29. Sheibani K, Winberg CD, van de Velde S, et al. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases. Am J Pathol 1987; 127:27-37.
30. Barnett D, Wilson GA, Lawrence AC, et al. The interleukin-2 receptor and its expression in the acute leukaemias and lymphoproliferative disorders. Dis Markers 1988; 6:133-139.
31. Rosolen A, Nakanishi M, Poplack DG, et al. Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies. Blood 1989; 73:1968-1972.
32. Kung E, Meissner K, Loning T. Cutaneous T cell lymphoma: immunocytochemical study on activation/proliferation and differentiation associated antigens in lymph nodes, skin, and peripheral blood. Virchows Arch A Pathol Anat Histopathol 1988; 413:539-549.
33. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79:2547-2554.
34. 486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994; 73:1276-1285.
35. Hesketh P, Caguioa P, Koh H, et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 1993; 11:1682-1690.
36. 486IL-2 in hematological cancers. Cancer Res 1993; 53:3930-3934.
37. 486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk Lymphoma 1993; 11:369-377.
38. 486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994; 84:1765-1774.
39. Choe S, Bennett MJ, Fujii G, et al. The crystal structure of diphtheria toxin. Nature 1992; 357:216-222.
40. Kiyokawa T, Williams DP, Snider CE, et al. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng 1991; 4:463-468.
41. 389EGF, epidermal growth factor (EGF) receptortargeted fusion toxins. J Biol Chem 1991; 266:21118-21124.
42. Theodoulou M, Baselga J, Scher H. Phase I dose escalation study of the safety, tolerability, pharmacokinetics and biologic effects of DAB 389 EGF in patients with solid malignancies that express EGF receptors. Proc Am Soc Clin Oncol 1995; 14:480 (Abstract #1561).